Seeking a resilient, future-oriented investment that also secures EU residency?

Pharma fund

Portugal’s Golden Visa program remains one of the most attractive in Europe — and for discerning investors, the right fund can deliver both security and long-term value.

We are introducing access to a new Golden Visa-eligible fund, anchored in the pharmaceutical and healthcare sector — an industry with consistent global demand, strong innovation pipelines, and resistance to economic cycles.

Why consider this opportunity?

- 500,000€ minimum investment for Golden Visa eligibility

- Exposure to a high-growth, essential industry

- Capital preservation focus, with risk mitigation at the core

- Strategic compliance with the evolving Portuguese regulatory landscape

- Potential for stable returns aligned with ESG and societal impact goals

- Fund size: 16M€

- Estimated ROI: 59,46%

- IRR: 7%

- Hurdle Rate: 3,5%

Pharma is more than a trend — it’s a long-term bet on global health, scientific advancement, and demographic shifts.

If you’re exploring a secure pathway to residency with strong fundamentals, this could be the right fit.

DM for more information, or reach out via www.mfg-consultants.com to request the brochure and a personalized briefing.

#GoldenVisaPortugal #PharmaInvestments #HNWI #InvestmentMigration #ResidencyByInvestment #PortugalInvestment #HealthcareFund #PrivateClients #PortugalGoldenVisa #SafeInvesting #AlternativeInvestments #GlobalMobility #WealthStrategy #PharmaSector